Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email:

Dr. Reddy’s Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

HYDERABAD, India & PRINCETON, N.J.–(EON: Enhanced Online News)–Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA).  “Acute migraine attacks are typically associated with pain and symptoms, […]

Opiant’s Intravail-based Nalmefene Provides Faster and Longer Treatment of Opioid Overdose

SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the U.S. Food […]

Aegis Announces Breakthrough in Non-Invasive, Rapid Onset, Acute Pain Control

SAN DIEGO, CA  Oct. 10, 2017/MarketWire – Aegis Therapeutics has developed a metered nasal spray   formulation of hydromorphone having rapid onset of drug action (approximately 1 min. with a Tmax of 7.5 min.) and high systemic bioavailability (approaching 100%) based upon Aegis’ patented Intravail® technology. These formulations offer the best pharmacokinetic performance of any non‐IV […]

Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder

SANTA MONICA, Calif., July 19, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced results from a Phase 1 trial of OPNT002, an intranasally dosed (IN) formulation of the opioid antagonist naltrexone hydrochloride (naltrexone), in development for the treatment of Alcohol […]

Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine

San Diego, CA, June 28, 2017 – Aegis Therapeutics announces positive Phase 2 results of DFN-02 using Intravail® technology. Dr. Reddy’s Laboratories in collaboration with Promius Pharma, LLC (a wholly owned subsidiary of DRL) is developing DFN-02, a novel intranasal migraine treatment using Intravail for the acute treatment of adults with migraine with or without […]

Aegis Awarded 10th Patent for Fast Acting Migraine Nasal Spray Treatment

SAN DIEGO, CA June 22, 2017/ NASDAQ — Aegis Therapeutics LLC announced today that it has been awarded Korean Patent No. 1719008, providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that […]

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

SAN DIEGO, May 4, 2017 /PRNewswire/ — Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, today announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration. “This trial achieved all its endpoints confirming that therapeutic doses of […]

Aegis’ Protek® Excipients Provide A Superior Alternative To Polysorbates In Preventing Protein Aggregation And Unwanted Oxidative Damage And Immunogenicity

SAN DIEGO, CA March 23, 2016 — Biotherapeutics incorporating alkylglucosides rather than polysorbates are likely to achieve substantial commercial benefits and a strong and differentiable market franchise for innovator biotherapeutics and biosimilars. Aggregation-induced neutralizing antibodies and anaphylactic reactions sometimes associated with polysorbates are serious and growing concerns of both the FDA and the European Medicines […]